These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 20645167)
21. The pharmacology of selective inhibition of COX-2. Grosser T Thromb Haemost; 2006 Oct; 96(4):393-400. PubMed ID: 17003913 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors. Gierse J; Nickols M; Leahy K; Warner J; Zhang Y; Cortes-Burgos L; Carter J; Seibert K; Masferrer J Eur J Pharmacol; 2008 Jun; 588(1):93-8. PubMed ID: 18457826 [TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4-formation. Schühly W; Hüfner A; Pferschy-Wenzig EM; Prettner E; Adams M; Bodensieck A; Kunert O; Oluwemimo A; Haslinger E; Bauer R Bioorg Med Chem; 2009 Jul; 17(13):4459-65. PubMed ID: 19481465 [TBL] [Abstract][Full Text] [Related]
24. Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Scholz M; Ulbrich HK; Soehnlein O; Lindbom L; Mattern A; Dannhardt G Bioorg Med Chem; 2009 Jan; 17(2):558-68. PubMed ID: 19097798 [TBL] [Abstract][Full Text] [Related]
25. Differential effects of COX inhibitors against beta-amyloid-induced neurotoxicity in human neuroblastoma cells. Ferrera P; Arias C Neurochem Int; 2005 Dec; 47(8):589-96. PubMed ID: 16169124 [TBL] [Abstract][Full Text] [Related]
26. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. Patrignani P; Panara MR; Sciulli MG; Santini G; Renda G; Patrono C J Physiol Pharmacol; 1997 Dec; 48(4):623-31. PubMed ID: 9444611 [TBL] [Abstract][Full Text] [Related]
27. High-throughput screening assays for cyclooxygenase-2 and 5-lipoxygenase, the targets for inflammatory disorders. Kumar KA; Reddy TC; Reddy GV; Reddy DB; Mahipal SV; Sinha S; Gaikwad AN; Reddanna P Indian J Biochem Biophys; 2011 Aug; 48(4):256-61. PubMed ID: 22053694 [TBL] [Abstract][Full Text] [Related]
28. [New NSAIDS: COX-1, COX-2, what about them?]. Peretz A Rev Med Brux; 1998 Sep; 19(4):A399-402. PubMed ID: 9805982 [TBL] [Abstract][Full Text] [Related]
29. Potency and selectivity of carprofen enantiomers for inhibition of bovine cyclooxygenase in whole blood assays. Brentnall C; Cheng Z; McKellar QA; Lees P Res Vet Sci; 2012 Dec; 93(3):1387-92. PubMed ID: 22703724 [TBL] [Abstract][Full Text] [Related]
30. Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Cappon GD; Cook JC; Hurtt ME Birth Defects Res B Dev Reprod Toxicol; 2003 Feb; 68(1):47-56. PubMed ID: 12852483 [TBL] [Abstract][Full Text] [Related]
31. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). Corazzi T; Leone M; Maucci R; Corazzi L; Gresele P J Pharmacol Exp Ther; 2005 Dec; 315(3):1331-7. PubMed ID: 16144976 [TBL] [Abstract][Full Text] [Related]
32. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Mastbergen SC; Jansen NW; Bijlsma JW; Lafeber FP Arthritis Res Ther; 2006; 8(1):R2. PubMed ID: 16356188 [TBL] [Abstract][Full Text] [Related]
35. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. Gerstenfeld LC; Thiede M; Seibert K; Mielke C; Phippard D; Svagr B; Cullinane D; Einhorn TA J Orthop Res; 2003 Jul; 21(4):670-5. PubMed ID: 12798067 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1. Lu ZH; Xiong XY; Zhang BL; Lin GC; Shi YX; Liu ZG; Meng JR; Zhou YM; Mei QB Acta Pharmacol Sin; 2005 Dec; 26(12):1505-11. PubMed ID: 16297351 [TBL] [Abstract][Full Text] [Related]
37. Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib. Giraudel JM; Toutain PL; King JN; Lees P J Vet Pharmacol Ther; 2009 Feb; 32(1):31-40. PubMed ID: 19161453 [TBL] [Abstract][Full Text] [Related]
38. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series. Song Y; Connor DT; Doubleday R; Sorenson RJ; Sercel AD; Unangst PC; Roth BD; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD J Med Chem; 1999 Apr; 42(7):1151-60. PubMed ID: 10197959 [TBL] [Abstract][Full Text] [Related]
39. Trihydroxyflavones with antioxidant and anti-inflammatory efficacy. Gomes A; Couto D; Alves A; Dias I; Freitas M; Porto G; Duarte JA; Fernandes E Biofactors; 2012; 38(5):378-86. PubMed ID: 22806885 [TBL] [Abstract][Full Text] [Related]
40. Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells. Ganesh R; Marks DJ; Sales K; Winslet MC; Seifalian AM World J Surg Oncol; 2012 Sep; 10():200. PubMed ID: 23013454 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]